# Belimumab in Remission of VASculitis

> **NCT01663623** · PHASE3 · COMPLETED · sponsor: **Human Genome Sciences Inc., a GSK Company** · enrollment: 106 (actual)

## Conditions studied

- Vasculitis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Belimumab 10 mg/kg
- **DRUG:** Azathioprine

## Key facts

- **NCT ID:** NCT01663623
- **Lead sponsor:** Human Genome Sciences Inc., a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-20
- **Primary completion:** 2017-02-06
- **Final completion:** 2017-02-06
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2018-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663623, "Belimumab in Remission of VASculitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01663623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*